Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Young, Summer E ^a   Duvernay, Matthew T ^a   Schulte, Michael L ^a   Lindsley, Craig W ^a   Hamm, Heidi E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 BENZYL 1H INDAZOL 3 YL)BENZOIC ACID ETHYL ESTER; INDOLE DERIVATIVE; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VU 046154; VU 0461954; VU 0469133; VU 0469150; VU 0469152; VU 0469153; VU 0469155; VU 0469897; VU 0469898; VU 0469899; VU 0469900; VU 0469901; VU 0469902; VU 0469903; VU 0469904; VU 0469905; VU 0469906; VU 0469907; VU 0469908; VU 0469909; VU 0469910; VU 0476680; VU 0476683; VU 0476684; VU 0476686; VU 0476689;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; MALE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

ADULT; BLOOD PLATELETS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INDAZOLES; INDOLES; MALE; PLATELET ACTIVATION; RECEPTORS, THROMBIN;

EID: 84878942827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065528     Document Type: Article

References (36)

1. Vu TK, Hung DT, Wheaton VI, Coughlin SR, (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068.
2. Kahn M, Zheng Y, Huang W, Bigornia V, Zeng D, et al. (1998) A dual thrombin receptor system for platelet activation. Nature 394: 690-694.
3. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR, (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. The Journal of clinical investigation 103: 879-887.
4. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, et al. (1998) Cloning and characterization of human protease-activated receptor 4. Proceedings of the National Academy of Sciences of the United States of America 95: 6642-6646.
5. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR, (2001) Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413: 74-78.
6. Hamilton JR, Cornelissen I, Coughlin SR, (2004) Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2: 1429-1435.
7. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, et al. (1996) Development of potent thrombin receptor antagonist peptides. J Med Chem 39: 4879-4887.
8. Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, et al. (1999) Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proceedings of the National Academy of Sciences of the United States of America 96: 12257-12262.
9. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, et al. (2000) Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60: 1425-1434.
10. Clasby MC, Chackalamannil S, Czarniecki M, Doller D, Eagen K, et al. (2006) Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists. Bioorg Med Chem Lett 16: 1544-1548.
11. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, et al. (2012) Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine 366: 1404-2817.
12. Tricoci P, Huang Z, Held C, Moliterno D, Armstrong P, et al. (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. The New England journal of medicine 366: 20-53.
13. Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, et al. (2012) Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 380: 1317-1324.
14. Duvernay MT, Young S, Gailani D, Schoenecker J, Hamm HE (2013) Protease-activated Receptor (PAR) 1 and PAR4 Differentially Regulate Factor V Expression from Human Platelets. Mol Pharmacol.
15. Cleator J, Zhu W, Vaughan D, Hamm H, (2006) Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood 107: 2736-2780.
16. Holinstat M, Boutaud O, Apopa P, Vesci J, Bala M, et al. (2011) Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis. Arteriosclerosis, thrombosis, and vascular biology 31: 435-477.
17. Holinstat M, Voss B, Bilodeau M, McLaughlin J, Cleator J, et al. (2006) PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. The Journal of biological chemistry 281: 26665-26739.
18. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR, (2000) Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. The Journal of biological chemistry 275: 25216-25221.
19. Voss B, McLaughlin J, Holinstat M, Zent R, Hamm H, (2007) PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Molecular pharmacology 71: 1399-1805.
20. Chen H-S, Kuo S-C, Teng C-M, Lee F-Y, Wang J-P, et al. (2008) Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorganic & medicinal chemistry 16: 1262-1340.
21. Peng C-Y, Pan S-L, Pai H-C, Tsai A-C, Guh J-H, et al. (2010) The indazole derivative YD-3 specifically inhibits thrombin-induced angiogenesis in vitro and in vivo. Shock (Augusta, Ga) 34: 580-585.
22. Wu C, Huang S, Hwang T, Kuo S, Lee F, et al. (2000) YD-3, a novel inhibitor of protease-induced platelet activation. British journal of pharmacology 130: 1289-1385.
23. Wu C-C, Hwang T-L, Liao C-H, Kuo S-C, Lee F-Y, et al. (2002) Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thrombosis and haemostasis 87: 1026-1059.
24. Lee F, Lien J, Huang L, Huang T, Tsai S, et al. (2001) Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents. Journal of medicinal chemistry 44: 3746-3755.
25. Peng CY, Pan SL, Pai HC, Tsai AC, Guh JH, et al. (2010) The indazole derivative YD-3 specifically inhibits thrombin-induced angiogenesis in vitro and in vivo. Shock 34: 580-585.
26. Kennedy JP, Williams L, Bridges TM, Daniels RN, Weaver D, et al. (2008) Application of combinatorial chemistry science on modern drug discovery. J Comb Chem 10: 345-354.
27. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, et al. (2005) Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15: 761-764.
28. Mistry AG, Smith K, Bye MR, (1986) A superior synthethic method for the bromination of indoles and benzimidazoles. Tetrahedron letters 27: 1051-2105.
29. Kudo N, Perseghini M, Fu G, (2006) A versatile method for Suzuki cross-coupling reactions of nitrogen heterocycles. Angewandte Chemie (International ed in English) 45: 1282-1286.
30. Cavallini L, Coassin M, Alexandre A, (1995) Two classes of agonist-sensitive Ca2+ stores in platelets, as identified by their differential sensitivity to 2,5-di-(tert-butyl)-1,4-benzohydroquinone and thapsigargin. Biochem J 310 (Pt 2): 449-452.
31. Jardin I, Ben Amor N, Bartegi A, Pariente JA, Salido GM, et al. (2007) Differential involvement of thrombin receptors in Ca2+ release from two different intracellular stores in human platelets. Biochem J 401: 167-174.
32. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
33. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, et al. (2002) Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost 87: 1026-1033.
34. Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rudiger S, et al. (2000) Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 83: 915-922.
35. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, et al. (1995) Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 26: 1665-1671.
36. Dormann D, Clemetson KJ, Kehrel BE, (2000) The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 96: 2469-2478.